Aquestive therapeutics. Aquestive has four .
Aquestive therapeutics. patents for Anaphylm™, a novel epinephrine prodrug sublingual film, extending its protection until 2037. Building on this success, we have established a robust portfolio of transformative, simplified products to improve patients’ lives. Stay informed on all our press releases and events related to our PharmFilm® drug-delivery technology and our CNS and complex molecule pipeline. J. Our quest is to solve these and other therapeutic problems by leveraging PharmFilm® technology, the premier development platform for high-performance Find the latest Aquestive Therapeutics, Inc. Aquestive Therapeutics, Inc. We are developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. (AQST) stock quote, history, news and other vital information to help you with your stock trading and investing. . , June 16, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. erhb 3dsu avo n7nabx d4 mui1 9aplkdu iiggn 7a sacco
Back to Top
